TEK2day FINANCE Open Terminal →

Surrozen, Inc. (SRZN)

NCM · Healthcare · Biotechnology

$23.39 +0.09%

Closing price as of 2026-06-12 · Source: TEK2day Finance

1-Year Price History +148.8% over period
$35$28$21$14$7 2025-062025-092025-122026-032026-06

Key Metrics

Market Cap
$309.8M
P/S (TTM)
41.3x
Exchange
NCM

About Surrozen, Inc.

Surrozen, Inc., a biotechnology company, discovers and develops product candidates to selectively modulate the Wnt pathway for tissue repair. Its lead product candidates are antibody-based therapeutics that target various disease areas, including diseases of the eye, intestine, liver, lung, retina, kidney, cochlea, cornea, skin, pancreas, and central nervous system. The company develops SZN-814, which combines Frizzled 4 (Fzd4 agonism) and vascular endothelial growth factor (VEGF antagonism) to treat diabetic macular edema (DME), neovascular age-related macular degeneration (wet AMD), and retinopathy indications; SZN-8143, which combines Fzd4 agonism, VEGF antagonism, and interleukin-6, or IL-6 for the treatment of DME/wet AMD/uveitic macular edema; and SZN-413, a Fzd4 targeted bi-specific antibody for the treatment of retinal vascular associated diseases. Surrozen, Inc. has a collaboration and license agreement with Boehringer Ingelheim International GmbH to research, develop, and commercialize Fzd4 bi-specific antibodies; and a research collaboration agreement with TCGFB, Inc. to discover antibody therapeutics targeting transforming growth factor beta, or TGF-ß, for the treatment of patients with idiopathic pulmonary fibrosis. Surrozen, Inc. was founded in 2015 and is headquartered in South San Francisco, California.

Quarterly Financials

Metric2025-06-302025-09-302025-12-312026-03-31
Revenue983K983K528K5.0M
Operating Income-9.0M-10.9M-12.6M-10.5M
Net Income39.7M-71.6M-183.2M-127.5M
Diluted EPS$2.55$-8.36$nan$-11.65

Annual Financials

Metric2022-12-312023-12-312024-12-312025-12-31
Revenue12.5M0.0010.7M3.5M
Operating Income-44.3M-43.0M-25.5M-42.1M
Net Income-36.0M-43.0M-63.6M-242.0M
Diluted EPS$-15.60$-21.33$-21.67$-32.37
Want live quotes, estimates, SEC filings, and CEO analytics for SRZN?
The free TEK2day terminal runs in your browser — type /SRZN to get started.
Open SRZN in the Terminal →